Preimplantation genetic testing for aneuploidy (PGT-A) typically involves a biopsy of cells from an embryo created through in vitro fertilization (IVF). These biopsied cells are then sent to a specialized genetics laboratory for analysis. The laboratory assesses the chromosomes within the cells to determine if there are any numerical abnormalities (too many or too few chromosomes), which are known as aneuploidies. Results from this analysis provide information about the chromosomal status of the embryo.
The timeframe for receiving these results plays a crucial role in the IVF process. Knowing the genetic makeup of the embryos allows for the selection and transfer of chromosomally normal embryos, potentially increasing the chances of a successful pregnancy and reducing the risk of miscarriage. Historically, waiting for these crucial results added a significant delay to the already complex IVF journey. Advancements in genetic testing technologies have, however, led to considerable improvements in turnaround times, minimizing this waiting period and allowing for more efficient treatment cycles.
